Gainsville, FL-based Applied Genetic Technologies announced that it has raised $11.8 million in financing. InterWest Partners led the round, and Intersouth Partners and MedImmune Ventures also participated.
AGTC says it will use the funds to complete the next phase of clinical trials for its gene therapy treatments for Alpha-1 Antitrypsin Deficiency (a form of emphysema) and Leber's Congenital Amaurosis (a form of childhood blindness). It will also pursue preclinical development of gene therapy treatment for a type of daytime blindness called Achromatopsia.
"We are delighted to have the support of such esteemed investors to advance our novel products through development," said Sue Washer, President and CEO of AGTC. "The clinical results stemming from the delivery of genes to correct inherited disorders are promising, especially for patients with genetic ocular diseases for which no treatment options are currently available."
- check out AGTC's release